The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. Methods: The MEDLINE/PubMed, EMBASE and ClinicalTrials.gov electronic databases were searched from inception to October 1, 2013, for randomized controlled trials (RCT), relevant open-label trials, meta-analyses and ongoing trials of pharmacological and psychotherapeutic approaches to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T 3 augmentation to be successful in TRD, most studies were carried out when participants were treated with tricyclic antidepressants (TCA). Of the available strategies to augment the response to new-generation antidepressants, the use of some atypical antipsychotics is best supported by evidence. Several novel therapeutic options are currently discussed. Evidence suggests that cognitive therapy (CT) is an effective strategy for TRD. Conclusions: The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies. Lithium and T 3 augmentation of TCA have the strongest evidence base for successful treatment of TRD. The use of augmentation of newer-generation antidepressants with atypical antipsychotics is supported by a growing evidence base. Current evidence supports CT as an effective strategy for TRD. There is a need for additional large-scale RCT of TRD. The development of new antidepressants targeting novel pathways opens a promising perspective for the management of TRD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Less common reactions were 'electric-shock' sensation [9,59,61,62] , visual and auditory hallucination [63] , nocturnal enuresis [64] , pruritus [65] , and emesis [6] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [63]
In the citing paper
“For example, anti-correlation, which refers to the selective reciprocal activation and deactivation of various brain regions, is critical for proper cognitive functioning.32”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [32]
In the citing paper
“In recent decades, the target clinical endpoints for MDD treatment have evolved from response (i.e. a 50 % reduction in severity of depressive symptoms from baseline) to the objective of clinical remission [49].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [49]
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Research works printed but not linked: 8
- 10.1176%2fappi.ps.60.11.1439 · doi:10.1176/appi.ps.60.11.1439 · Paper page
- 10.1192%2fbjp.175.1.12 · DOI · Paper page
- 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2fappi.ajp.163.9.1531 · DOI
- 10.1176%2fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1159%2f000334112 · DOI
- 10.3109%2f10401230209147396 · doi:10.3109/10401230209147396 · Paper page
- 10.1176%2fappi.ajp.164.5.739 · DOI · Paper page
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“The value of switching between classes or within classes of antidepressants remains controversial.(100) A previous meta-analysis (4 studies, N 1⁄4 1496) found a modest, but statistically significant, remission advantage for patients on an SSRI switched to an antidepressant in a different class (bupropion, mirtazapine,…”
BackgroundSelf-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Cognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“The trifecta of cognitive dysfunction, anhedonia, and depressed mood is thought to be a critical mediator of MDD-related functional disability.(6,11) These interconnected domains of depression contribute to self-perpetuating cycles of illness and impairment.”
BackgroundSelf-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Dandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
Self-citationCognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
“a 50 % reduction in severity of depressive symptoms from baseline) to the objective of clinical remission [49].”
BackgroundSelf-citationFonagy, P., Rost, F., Carlyle, J., McPherson, S., Thomas, R., Pasco Fearon, R. M., Goldberg, D., & Taylor, D. (2015) · World Psychiatry · doi:10.1002/wps.20267 · Cited by 237
“Recent systematic reviews of treatment research for this patient group, whether considered separately (7) or combined with chronic major depressive disorder (8), revealed that existing studies are mostly of poor quality and design (9).”
BackgroundINDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
Baru, P. C. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 236
Lithium: A review of pharmacology, clinical uses, and toxicity
Oruch, R., Elderbi, M. A., Khattab, H. A., Pryme, I. F., & Lund, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.042 · Cited by 221
De Carlo, V., Calati, R., & Serretti, A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.034 · Cited by 217
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Monoaminergic system and depression
Perez-Caballero, L., Torres-Sanchez, S., Romero-López-Alberca, C., González-Saiz, F., Mico, J. A., & Berrocoso, E. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-2978-8 · Cited by 204
Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442260 · Cited by 187
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
“Only approximately 30% of patients with MDD achieve remission after an adequate trial with a standard antidepressant and the majority of individuals do not achieve long-term functional recovery [4].”
BackgroundSelf-citationIncreased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis.
Jonsson, S. W., Backman, C., Johnson, O., Karp, K. H., Lundström, E., Sundqvist, K., & Dahlqvist, S. R. (2001) · PubMed · Cited by 172
Guidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167
Psychological therapies for treatment-resistant depression in adults
Ijaz, S., Davies, P., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010558.pub2 · Cited by 155
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
“Notwithstanding the availability of many antidepressants, exerting their effects mainly through the inhibition of monoamine reuptake, the majority of individuals with MDD do not achieve full remission [7].”
Backgroundvan Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
“Clinical reviews suggest a prevailing inclination to manage TRD (solely) by pharmacotherapy or other somatic treatments while scarcely mentioning studies into psychotherapy for TRD with little or no discussion of the findings and prospects (e.g. Carvalho et al., 2014; Dold and Kasper, 2016).”
BackgroundDifficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“Therapy aimed at helping patients become skeptics of their pervasively negative views can enhance self-esteem and their engagement in satisfying activities (Carvalho et al., 2014), mitigating in part the effects of a chronically depressed state.”
BackgroundRocha, R. B., Dondossola, E. R., Grande, A. J., Colonetti, T., Ceretta, L. B., Passos, I. C., Quevedo, J., & da Rosa, M. I. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.08.004 · Cited by 119
Proteomic Profiling Reveals Microbiota-Driven Sensing Mechanisms of Gut-Brain Axis in Depression
Liu, Y., Luo, Y., Zeng, B., Gui, S., Zheng, P., Zheng, P., Pu, J., Wang, H., Wu, Y., Zhou, C., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-021-01689-w · Cited by 120
“MDD is one of the leading causes of disability worldwide [1], and >50% of patients do not remit after first-line antidepressant treatment despite numerous advances in the pharmacological treatment of depression [2].”
BackgroundRybak, Y. E., Lai, K. S. P., Ramasubbu, R., Vila‐Rodriguez, F., Blumberger, D. M., Chan, P., Delva, N., Giacobbe, P., Gosselin, C., Kennedy, S. H., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23135 · Cited by 97
“There exists mixed evidence regarding the advantages of prescribing medications from the same class or different classes and therefore this study deliberately did not explore this (Bschor et al., 2018; Carvalho et al., 2014).”
BackgroundMood and Anxiety Disorders as Early Manifestations of Medical Illness: A Systematic Review
Cosci, F., Fava, G. A., & Sonino, N. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000367913 · Cited by 109
Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
Carvalho, A., Miskowiak, K., Hyphantis, T., Kohler, C., Alves, G., Bortolato, B., G. Sales, P., Machado-Vieira, R., Berk, M., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203627 · Cited by 107
“Lithium also is an effective augmenting agent for treatmentresistant depression [253], and evidences indicate its effectiveness for suicide prevention among populations with mood disorders [254].”
BackgroundSelf-citationAbuse and misuse of antidepressants
Sullivan, M., & Evans, E. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37917 · Cited by 91
“an effective strategy for depression, including treatmentresistant depression.(157) The addition of cognitive-behavioral”
Dodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1851052 · Cited by 88
“Pharmacotherapeutic strategies are commonly proposed, including augmentation (Edwards et al. 2013; Carvalho et al. 2014) or combination therapy (Thomas et al. 2015), as well as other treatments including neurostimulation (including transcranial magnetic stimulation (Emond et al. 2013) and…”
BackgroundSelf-citationFava, G. A. (2016) · The Wiley Handbook of Positive Clinical Psychology · doi:10.1002/9781118468197.ch26 · Cited by 105
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Fava, G. A., Cosci, F., Guidi, J., & Tomba, E. (2017) · Depression and Anxiety · doi:10.1002/da.22629 · Cited by 95
Visentin, A. P. V., Colombo, R., Scotton, E., Fracasso, D. S., Rosa, A. R., Branco, C. S., & Salvador, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2972968 · Cited by 88
Kanchanatawan, B., Tangwongchai, S., Sughondhabhirom, A., Suppapitiporn, S., Hemrunrojn, S., Carvalho, A. F., & Maes, M. H. J. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9860-4 · Cited by 78
“Moreover, approved antidepressant agents supposedly act through the modulation of serotonergic pathways, but evidence indicates that only approximately a third of patients with major depression achieve remission after a trial with a first-line antidepressant agent (Carvalho et al. 2014).”
Self-citationBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 71
“Novel pathways of particular interest are the following: the inflammatory pathways, the oxidative and nitrosative stress (O&NS) pathways, the hypothalamicpituitary-adrenal (HPA) axis, neurotrophic signaling pathways, the metabolic and bioenergetics system, the glutamate system, the opioid system and the cholinergic sy…”
BackgroundSelf-citationPapakostas, G. I., Trivedi, M. H., Shelton, R. C., Iosifescu, D. V., Thase, M. E., Jha, M. K., Mathew, S. J., DeBattista, C., Dokucu, M. E., Brawman‐Mintzer, O., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02468-x · Cited by 73
“Despite both augmentation with atypical antipsychotic agents and switching to a different antidepressant class having well-established ef fi cacy, strikingly, there has never been a direct comparison of them for TRD [11] .”
BackgroundRodent models of treatment-resistant depression
Caldarone, B. J., Zachariou, V., & King, S. L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.063 · Cited by 50
“Overall, findings on augmentation with atypical antipsychotics have been positive (Carvalho et al, 2014; Kato and Chang, 2013).”
BackgroundCordeiro, R. C., Filho, A. J. M. C., Gomes, N. S., Tomaz, V. D. S., Medeiros, C. D., Queiroz, A. I. D. G., Maes, M. H. J., Macêdo, D. S., & Carvalho, A. F. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00125 · Cited by 60
Self-citationBehavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55
“Treatment resistance is another area where previous history of behavioral toxicity, particularly related to the development of tolerance upon antidepressant treatment,(19) should be considered.(33)”
Background‘Cool’ and ‘Hot’ executive functions in suicide attempters with major depressive disorder
Ho, M.-C., Hsu, Y.-C., Lu, M.-L., Gossop, M., & Chen, V. C.-H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.057 · Cited by 52
“Only approximately 30% of patients with MDD achieve remission after an adequate trial with a standard antidepressant, and the majority of individuals do not achieve long-term functional recovery (Carvalho et al., 2014).”
BackgroundChen, M., Pan, T., Hsu, J.-W., Huang, K., Su, T., Li, C., Lin, W.-C., Tsai, S., Chang, W.-H., Chen, T., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.09.369 · Cited by 53
Carter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., et al. (2020) · International Review of Psychiatry · doi:10.1080/09540261.2020.1765748 · Cited by 47
Self-citationDepression in the medically ill
Rosenblat, J. D., Kurdyak, P. A., Cosci, F., Berk, M., Maes, M. H. J., Brunoni, A. R., Li, M., Rodin, G., McIntyre, R. S., & Carvalho, A. F. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419888576 · Cited by 54
“Several novel interventions primarily acting outside of the monoaminergic system are under investigation (Carvalho et al., 2014; Rosenblat et al., 2015).”
BackgroundSelf-citationBrownstein, D. J., Salagre, E., Köhler, C., Stubbs, B., Vian, J., Pereira, C., Chavarria, V., Karmakar, C., Turner, A., Quevedo, J., et al. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417721654 · Cited by 46
“This is aggravated by the lack of novel interventions capable of ameliorating depressive symptoms (Berk et al., 2011; Carvalho et al., 2014), and increasing attention and efforts are being paid to the repurposing of diverse and already developed drugs to psychiatric disorders.”
BackgroundSelf-citationStimulants for depression: On the up and up?
Malhi, G. S., Byrow, Y., Bassett, D., Boyce, P., Hopwood, M., Lyndon, W., Mulder, R., Porter, R., Singh, A., & Murray, G. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416634208 · Cited by 46
“Consequently, treatment guidelines do not advocate the use of traditional psychostimulants in the treatment of depression (Carvalho et al., 2014; Malhi et al., 2015a).”
BackgroundLuan, S., Zhou, B., Wu, Q., Wan, H., & Li, H. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.101983 · Cited by 48
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
The Neglected Role of Psychotherapy for Treatment-Resistant Depression
Markowitz, J. C., Wright, J. H., Peeters, F., Thase, M. E., Kocsis, J. H., & Sudak, D. M. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21050535 · Cited by 41
Han, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 41
Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders
Ikram, M. A., Ullah, R., Khan, A., & Kim, M. O. (2020) · Cells · doi:10.3390/cells9061464 · Cited by 36
“Although significant efforts have been made to lighten the load of the disease symptoms, only one-third of patients achieve remission after an adequate trial period with first-line antidepressant treatment [36].”
BackgroundWang, H. R., Woo, Y. S., Ahn, H. S., Ahn, I. M., Kim, H. J., & Bahk, W.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv023 · Cited by 31
“Previous articles include three meta-analyses (Papakostas et al., 2007; Nelson and Papakostas, 2009; Spielmans et al., 2013), one Cochrane review (Komossa et al., 2010), and several other review articles (Chen et al., 2011; Kato and Chang, 2013; Wright et al., 2013) that have demonstrated the efficacy of atypical anti…”
BackgroundInfluentialmiR‑155 mediates inflammatory injury of hippocampal neuronal cells via the activation of microglia
Sun, X., Song, M.-F., Song, H., Wang, Y., Luo, M., & Yin, L. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9917 · Cited by 35
“At present, the treatment strategies for TRD, involve increasing the dosage and course of anti-depressants, altering or using other antidepressants, adding synergists and combining with non‑drug therapy (5).”
Athreya, A. P., Brückl, T. M., Binder, E. B., Rush, A. J., Biernacka, J. M., Frye, M. A., Neavin, D. R., Skime, M. K., Monrad, D., Iyer, R. K., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00943-x · Cited by 34
“As a consequence, antidepressant treatment selection occurs on a “try-and-try-again” basis, based on lack of perceived treatment benefit by patients and clinicians [6].”
BackgroundClinical improvements following bilateral anterior capsulotomy in treatment-resistant depression
Subramanian, L., Bracht, T., Jenkins, P., Choppin, S., Linden, D. E. J., Phillips, G., & Simpson, B. (2016) · Psychological Medicine · doi:10.1017/s0033291716003159 · Cited by 34
“Current first-line treatments for depression are antidepressant medication and psychotherapy, but 70% of patients do not respond to the first choice of treatment (Carvalho et al. 2014).”
BackgroundThe role of GRIK4 gene in treatment-resistant depression
Milanesi, E., Bonvicini, C., Congiu, C., Bortolomasi, M., Gainelli, G., Gennarelli, M., & Minelli, A. (2015) · Genetics Research · doi:10.1017/s0016672315000142 · Cited by 28
“MDD is one of the most prevalent mental disorders worldwide with a profound impact on public health (Carvalho et al ., 2014).”
Zhang, K., Liu, R., Zhang, J., Wei, X., Gao, Y., Ma, W., Li, Y., Cai, W., & Shen, W. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2146001 · Cited by 28
Asaoka, N., Nagayasu, K., Nishitani, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.032 · Cited by 26
Wu, G., & Baeken, C. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9510-0 · Cited by 22
Pathogenic beliefs among patients with depressive disorders
Neelapaijit, A., Wongpakaran, T., Wongpakaran, N., & Thongpibul, K. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136212 · Cited by 20
“20,21 How pathogenic beliefs can be attributed to treatment-resistant depression is not yet clear.”
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Rahman, R. R., Hamirani, M. M., Hodsoll, J. P., Carvalho, A. F., Husain, N., & Young, A. H. (2019) · BJPsych Open · doi:10.1192/bjo.2018.84 · Cited by 18
Self-citationHe, J., Yang, L., Li, D., Xie, J., Zhou, G., Zhou, R., Li, Y., Wei, G., Gong, Z., Li, L., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138352 · Cited by 16
Yang, J., Zhu, X., Hu, H., & Lin, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-518 · Cited by 15
“Previous studies have demonstrated that SOCS1, IKK, SMAD2 and CEBPβ behaved as downstream target molecules of miR155 during microglial activation (19,20).”
ResultWang, Y., Li, S., Niu, L., Ma, Y., Qiu, Y., Li, S., Guobule, N., Cao, H., & Li, J. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02415-y · Cited by 14
“1/3 MDD patients showed treatment-refractory after recerving multiple pharmacological treatments despite significant improvements in depressive symptoms under the treatment of antidepressants (Carvalho et al. 2014).”
BackgroundDepression in the Medically Ill: An Integrated Approach
Rodin, G., Craven, J., & Littlefield, C. H. (2017) · Routledge eBooks · doi:10.4324/9781315094991 · Cited by 14
Corticosterone-induced Hippocampal 5-HT Responses were Muted in Depressive-like State
Sun, X., Zu, Y., Li, X., Zhao, S., Sun, X., Li, L., Zhang, X., Wang, W., Liang, Y., Wang, W., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00334 · Cited by 15
Ambresin, G., Leuzinger‐Bohleber, M., Fischmann, T., Axmacher, N., Hattingen, E., Bansal, R., & Peterson, B. S. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05287-6 · Cited by 16
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
“3,4 Suicidal ideation is a critical risk factor for poor prognosis of MDD, regardless of whether TRD is present or not.”
Hu, Y., Ali, T., Mou, S., Gong, Q., Gao, R., Luo, Y., Li, S., Li, L., & Hao, L. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10180-y · Cited by 12
“Despite receiving first-line monoaminergic antidepressant therapy, one-third of patients do not experience remission after a sufficient trial (Carvalho et al. 2014).”
RETRACTED: Exploring the role of biologics in depression
Rani, T., Behl, T., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Meraya, A. M., Bhatia, S., & BUNGAU, S. G. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110409 · Cited by 12
RetractedGonçalves, C. L., Abelaira, H. M., Rosa, T., de Moura, A. B., Veron, D. C., Borba, L. A., Botelho, M. E. M., Goldim, M. P. D. S., Garbossa, L., Fileti, M. E., et al. (2021) · Pharmacological Reports · doi:10.1007/s43440-020-00200-4 · Cited by 12
Danyang, L., Yang, J., Jin, W., Zhong, Q., & Zhou, T. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03349-w · Cited by 12
Noninvasive Capsulotomy for Refractory Depression by Frameless Stereotactic Radiosurgery
Khattab, M. H., Sherry, A. D., Devan, S. P., Luo, G., Chaballout, B. H., Jean-Baptiste, S., Xu, J., Bick, S. K. B., Petrie, W. M., & Cmelak, A. J. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.04.042 · Cited by 12
Number of illness episodes as predictor of residual symptoms in major depressive disorder
Serafini, G., Nebbia, J., Cipriani, N., Conigliaro, C., Erbuto, D., Pompili, M., & Amore, M. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2017.09.026 · Cited by 11
Chen, X., Liu, Y., Pu, J., Gui, S., Wang, D., Zhong, X., Chen, W., Wei, T., Chen, Y., Chen, X. '., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.031 · Cited by 11
dos Santos, B. M., Pereira, G. C., Piton, E., Fialho, M. F. P., Becker, G., Carlotto, M. D. S., Camargo, L. F. M., Ramanzini, L. G., Oliveira, S. M., Trevisan, G., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113815 · Cited by 13
Corral, R. M., Giraldo, E. B., Cetkovich, M., Córdoba, R., Chestaro, J., Gama, C. S., Bonetto, G. G., López‐Jaramillo, C., Moreno, R. A., Ng, B., et al. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2023.06.001 · Cited by 11
Sun, Q., Yuan, F., Yuan, R., Ren, D., Zhu, Y., Bi, Y., Hu, J., Guo, Z., Xu, F., Niu, W., et al. (2019) · Medicine · doi:10.1097/md.0000000000015456 · Cited by 11
Garcia-Toro, M., Aguilar-Latorre, A., Garcia, A., Navarro-Guzmán, C., Gervilla, E., Seguí, A., Gazquez, F., Marino, J. A., Gomez-Juanes, R., Serrano-Ripoll, M. J., et al. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1008891 · Cited by 10
“The inclusion criteria were: (Fava, 2003) 18 years old or older; (Mrazek et al., 2014) having a diagnosis of MDD based on the DSM-5 and Mini-International Neuropsychiatric Interview (MINI) criteria (Ferrando et al., 2000); (Foroughi et al., 2020) having at least two failed antidepressant treatment attempts or refusal…”
BackgroundNovel Augmentation Strategies in Major Depression.
Martiny, K. (2017) · PubMed · Cited by 12
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study
Specka, M., Bonnet, U., Schmidberg, L. M., Wichmann, J. L., Keller, M., Scholze, C., & Scherbaum, N. (2024) · Pharmacopsychiatry · doi:10.1055/a-2215-6114 · Cited by 10
“One option after non-response to a first-line agent is switching to a different antidepressant, a strategy associated with response rates between 17 % and 70 % in double-blind and open-label studies [4, 5].”
BackgroundCatalano, G., Robeel, R., Cheney, G. A., Spurling, B. C., Catalano, M. C., Schultz, S. K., & Sanchez, D. L. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001236 · Cited by 12
Bech, P., Lindberg, L., Straasø, B., & Larsen, E. R. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.44 · Cited by 9
“However, the costs in connection with these patients (directly or indirectly) are over 50% of the total costs for depressive disorders (4).”
BackgroundWell-being Therapy in Depressive Disorders
Mansueto, G., & Cosci, F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_19 · Cited by 8
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 8
Xing, H., Liu, X., Zhang, Y., Wu, J., Li, M., Ye, H., Ding, Y., Wang, W., Zheng, Z., & Bao, T. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0151 · Cited by 6
Pathways Driving Neuroprogression in Depression: The Role of Immune Activation
Oriolo, G., Grande, I., Martín‐Santos, R., Vieta, E., & Carvalho, A. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00010-6 · Cited by 6
Self-citationRen, D., Bi, Y., Xu, F., Niu, W., Zhang, R., Hu, J., Guo, Z., Wu, X., Cao, Y., Huang, X., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.05.071 · Cited by 6
Zhao, H., Zhang, Y., Cui, H., Tang, L., Gao, Y., Tang, C., & Shen, W. (2026) · CNS Spectrums · doi:10.1017/s1092852926100868 · Cited by 6
“5 8 Research 9 has shown that 70% of patients exhibit inadequate response to initial antidepressant therapy, while 30 – 50% face relapse risk post-treatment cessation.”
The Efficacy of Bio- and Neurofeedback for Depression: A Meta-analysisPreprint
Fernández‐Álvarez, J., Grassi, M., Colombo, D., Colombo, D., Botella, C., Cipresso, P., Perna, G., & Riva, G. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/yhr7w · Cited by 5
Chen, Y., Liu, Y., Pu, J., Gui, S., Wang, D., Zhong, X., Wei, T., Chen, X., Chen, W., Chen, X., et al. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01403-x · Cited by 4
“However, these treatments are ineffective for over half of the patients (Carvalho et al. 2014), underscoring the need to elucidate the molecular mechanisms underlying the antidepressant response.”
Li, Y., Wang, D., Fang, J., Zu, S., Xiao, L., Zhu, X., Wang, G., & Hu, Y. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05915-9 · Cited by 5
“Nevertheless, even among patients who have achieved full symptomatic remission, depression-related residual symptoms may persist [3, 4], often influenced by multitude of factors [5, 6].”
BackgroundChen, F. (2018) · International Journal of Pharmacy and Chemistry · doi:10.11648/j.ijpc.20180403.11 · Cited by 4
“Depression may be considered resistant to treatment when at least two trials with antidepressants from different pharmacologic classes (adequate in dose, duration, and compliance) fail to produce a significant clinical improvement [2].”
BackgroundInfluentialWoo, Y. S., Bahk, W., Seo, J. S., Park, Y., Kim, W., Jeong, J., Shim, S.-H., Lee, J. G., Jang, S.-H., Wang, S., et al. (2021) · 신경정신의학 · doi:10.4306/jknpa.2021.60.3.174 · Cited by 4
Rafe, M. R., Waris, A., & Saha, P. (2025) · Health Science Reports · doi:10.1002/hsr2.70370 · Cited by 3
Souliotis, K. N., Golna, C., Samara, M. T., Tsapakis, E.-M., Bozikas, V. P., Hyphantis, T. N., Smyrnis, N., & Stefanis, N. C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1561821 · Cited by 3
“Currently, there is no established Standard of Care (SoC) for TRD, and there is wide variation in clinical approaches to overall disease management (6, 7).”
Self-citationNLRP3 in the dorsal raphe nucleus manipulates the depressive-like behaviors
Cai, J., Zhao, J., Peng, R., Yu, H., He, Y., Zhou, Q., Wang, Y., & Xie, P. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111405 · Cited by 4
“Though the availability of antidepressants is increasing in recent years, there are still many patients who do not respond to the treatment with first-line antidepressants [11] .”
Treatment-Resistant Depression: An Overview
Moukaddam, N. J., & Shah, A. A. (2016) · Psychiatric Annals · doi:10.3928/00485713-20160215-01 · Cited by 4
Big Data Guided Interventions: Predicting Treatment Response
Kautzky, A., Lanzenberger, R. R., & Kasper, S. F. (2019) · Springer eBooks · doi:10.1007/978-3-030-03553-2_4 · Cited by 3
SMARTs with treatment preference: Pragmatic SMART design and methods motivated by STAR*D
Medley, S., Wank, M., Tamura, R., Braun, T., & Kidwell, K. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108162 · Cited by 3
Cioffi, A., Bersani, G., & Rinaldi, R. (2020) · Medico-Legal Journal · doi:10.1177/0025817220923687 · Cited by 2
Research Progress on Cognitive Impairment and Insomnia in Patients with Depressive Disorder
杨, 滋. (2024) · Advances in Psychology · doi:10.12677/ap.2024.143149 · Cited by 2
Translational Medicine Strategies in Drug Development for Mood Disorders
Pan, Z., Grovu, R. C., & McIntyre, R. S. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00023-0 · Cited by 2
Self-citation
Metadata
- Authors
- Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S.
- Affiliations
- Universidade Federal do Ceará (BR)
- Deakin University (AU)
- University of Ioannina (GR)
- University Health Network (CA)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 83
- Issue
- 2
- Pages
- 70-88
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1969922688
- Cited by
- 123
- References
- 168
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 6
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Deakin Research Online (Deakin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant switching, antidepressant combination therapy, lithium augmentation, tricyclic antidepressants, atypical antipsychotics, cognitive therapy, newer antidepressants, psychotherapy
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Antidepressive Agents, Second-Generation, Drug Substitution, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.